Under these conditions, PD-1/PD-L1 blockade can provide some rescue of effector T cell function [16] and recent clinical trials of PD-1 and PD-L1 blockade in cancer have shown very promising outcomes [20,21]. The gene discussed is CD274; the disease is cancer.